Real-world experience of erenumab in patients with chronic or episodic migraine in the UAE

BACKGROUND: Erenumab is a fully human monoclonal antibody and a highly potent, first-in-class calcitonin gene-related peptide receptor inhibitor approved for migraine prevention in adults. Randomised, placebo-controlled trials show that erenumab treatment results in clinically meaningful responses,...

Descripción completa

Detalles Bibliográficos
Autores principales: Alsaadi, Taoufik, Noori, Suzan, Varakian, Razmig, Youssef, Saly, Almadani, AbuBaker
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9202108/
https://www.ncbi.nlm.nih.gov/pubmed/35710354
http://dx.doi.org/10.1186/s12883-022-02710-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9202108/
https://www.ncbi.nlm.nih.gov/pubmed/35710354
http://dx.doi.org/10.1186/s12883-022-02710-5

Ejemplares similares